Severe adverse reactions
Adverse events . | Patients, N . | % . | Time from treatment initiation, mo . | Maximum thalidomide dose, mg/d . |
|---|---|---|---|---|
| Symptomatic bradycardia* | 8 | 26 | 3.0 (0.2-6.9)‡ | 200 (100-400)‡ |
| Sedation/fatigue | 4 | 13 | 4.9 (0.5-7.2)‡ | 200 (100-400)‡ |
| Constipation | 2 | 7 | 0.7-2.8 | 100-200 |
| Acute dyspnea† | 2 | 7 | 1.9-5.1 | 300-400 |
| Deep venous thrombosis | 1 | 3 | 0.9 | 100 |
| Skin lesions | 1 | 3 | 0.5 | 100 |
| Epilepsy | 1 | 3 | 3.4 | 200 |
| Renal failure | 1 | 3 | 5.7 | 400 |
Adverse events . | Patients, N . | % . | Time from treatment initiation, mo . | Maximum thalidomide dose, mg/d . |
|---|---|---|---|---|
| Symptomatic bradycardia* | 8 | 26 | 3.0 (0.2-6.9)‡ | 200 (100-400)‡ |
| Sedation/fatigue | 4 | 13 | 4.9 (0.5-7.2)‡ | 200 (100-400)‡ |
| Constipation | 2 | 7 | 0.7-2.8 | 100-200 |
| Acute dyspnea† | 2 | 7 | 1.9-5.1 | 300-400 |
| Deep venous thrombosis | 1 | 3 | 0.9 | 100 |
| Skin lesions | 1 | 3 | 0.5 | 100 |
| Epilepsy | 1 | 3 | 3.4 | 200 |
| Renal failure | 1 | 3 | 5.7 | 400 |